Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Adriaan D de Jongh"'
Autor:
Adriaan D de Jongh, Nathalie Braun, Markus Weber, Michael A van Es, Pegah Masrori, Jan H Veldink, Philip van Damme, Leonard H van den Berg, Ruben P A van Eijk
Publikováno v:
Journal of neurology, neurosurgery, and psychiatry. 93(8)
BackgroundThe Gold Coast criteria (GCC) have been proposed as a means of selecting patients for amyotrophic lateral sclerosis (ALS) clinical trials. We aimed to characterise disease progression according to the GCC.MethodsData from population-based A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed63b6867c0552ae46537e02f59545ef
https://pubmed.ncbi.nlm.nih.gov/35654584
https://pubmed.ncbi.nlm.nih.gov/35654584
Autor:
Jaap N.E. Bakers, Adriaan D. de Jongh, Tommy M. Bunte, Lindsay Kendall, Steve S. Han, Noam Epstein, Arseniy Lavrov, Anita Beelen, Johanna M.A. Visser-Meily, Leonard H. van den Berg, Ruben P. A. van Eijk
Publikováno v:
Amyotrophic lateral sclerosisfrontotemporal degeneration. 23(7-8)
iObjective:/iUniform data collection is fundamental for multicentre clinical trials. We aim to determine the variability, between ALS trial centers, in the prevalence of unexpected or implausible improvements in the revised ALS functional rating scal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5887c8b967e8e7fa1aec9e4310201d2f
https://pubmed.ncbi.nlm.nih.gov/34949141
https://pubmed.ncbi.nlm.nih.gov/34949141
Autor:
Christopher J McDermott, Ruben P A van Eijk, Marinus J.C. Eijkemans, Noam Epstein, Adriaan D. de Jongh, Stavros Nikolakopoulos, Orla Hardiman, Henk-Jan Westeneng, Pamela J. Shaw, Arseniy Lavrov, Kit C.B. Roes, Ammar Al-Chalabi, Philip Van Damme, Tessa Kliest, Leonard H. van den Berg, Steve S.W. Han, Lindsay Kendall
Publikováno v:
Neurology, 97, 11, pp. 528-536
Neurology, 97, 528-536
Neurology, 97, 528-536
Development of effective treatments for amyotrophic lateral sclerosis (ALS) has been hampered by disease heterogeneity, a limited understanding of underlying pathophysiology, and methodologic design challenges. We have evaluated 2 major themes in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f181c65209ba5a93d32cd89513df643f
https://lirias.kuleuven.be/handle/123456789/682689
https://lirias.kuleuven.be/handle/123456789/682689
Autor:
Stavros Nikolakopoulos, Ruben P A van Eijk, Christopher J McDermott, Adriaan D. de Jongh, Kit C.B. Roes, Marinus J.C. Eijkemans, Leonard H. van den Berg
Publikováno v:
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 22, 3-4, pp. 300-307
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 22, 300-307
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 22, 300-307
Contains fulltext : 235577.pdf (Publisher’s version ) (Open Access) Objective: The ALSFRS-R is limited by multidimensionality, which originates from the summation of various subscales. This prevents a direct comparison between patients with identic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::876d5e5a995e052233ddd4c079879f69
https://eprints.whiterose.ac.uk/171282/1/21678421.2021.pdf
https://eprints.whiterose.ac.uk/171282/1/21678421.2021.pdf
Publikováno v:
Journal of Neurology, Neurosurgery & Psychiatry. 92:569-570
Clinical trials in amyotrophic lateral sclerosis (ALS) aim to identify treatments that can slow functional decline or prolong survival time. In the absence of objective biomarkers, questionnaires, such as the ALS Functional Rating Scale (ALSFRS), are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97b8c57a38ba3ff0c4c11e8a352540a5
https://doi.org/10.1136/jnnp-2020-325253
https://doi.org/10.1136/jnnp-2020-325253
Publikováno v:
Journal of neurology, neurosurgery, and psychiatry. 90(10):1183
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with a median survival of 3 years. Currently, riluzole is the only drug that can prolong the life expectancy of patients with ALS.1 In the original trial, riluzole prolonged med
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68a8ceecce015e96d504fa911b2ba254
https://doi.org/10.1136/jnnp-2018-320211
https://doi.org/10.1136/jnnp-2018-320211
Publikováno v:
European Journal of Haematology, 98(5), 478. Wiley-Blackwell
Background The dramatic impact of hemosiderosis on survival in chronically transfused patients with hereditary anemia is well known. We evaluated whether patients receiving multiple red blood cell (RBC) transfusions are adequately screened for hemosi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2312d21a92baac84215918217b42a542
https://pubmed.ncbi.nlm.nih.gov/28129458
https://pubmed.ncbi.nlm.nih.gov/28129458